A pipeline full of cures

The enormous unmet medical need represented by Lumen’s initial targets also demonstrates the size of its addressable markets.

Moving
Fast To Save
Millions
Of Lives

Oral biologic drugs are the fastest, safest, best way to generate new cures for many highly prevalent diseases that the conventional drug-making toolkit has failed to solve. This is particularly true for addressing unintended consequences of antibiotics and improving access to medicines in the developing world, but drug shortages are also a problem in the developed world for highly prevalent diseases like obesity and diabetes. Lumen’s technology offers new hope to these left-behind patients.

Pipeline

Disease Area

Mode of Action

MOA Previously
Demonstrated

Preclinical Phase 1
(safety) Phase 2
(proof of
concept) Phase 3
(definitive
efficacy)

Research &
Funding
Partners

Core pipeline

Obesity

Oral biologic

C. difficile (LMN-201)

Oral biologic cocktail

Product Candidate

C. difficile Colitis

(Clostridioides difficile)

Initiated Spring 2018

Mode of action: Cocktail of biologics; two formats

Phase 1

Traditionally considered a hospital-acquired infection, C. difficile is more commonly community - required today. For this reason, the shelf-stable, orally delivered format of Lumen’s product is an important addition to the tool kit for treating and preventing this disease. Long-term consequences include chronic diarrhea, severe intestinal inflammation, surgical resection, and death. Insidiously, the very thing that is used to treat this infection—broad spectrum antibiotics—is also the thing that causes the disease. . C. difficile therefore appears at the top of the CDC’s antimicrobial threats list year after year, and in 2009 was estimated to single-handedly drive 2.3% of all US hospital costs.

IBD (Crohn’s/UC)

Oral biologic cocktail

Product Candidate

IBD

(Crohn's disease and ulcerative colitis)

Initiated Summer 2021

Mode of action: Biologic cocktail

Preclinical

Inflammatory bowel disease (IBD) is a systemic autoimmune disease, but it has an obvious nexus with the gastrointestinal tract. The two main sub-varieties—Crohn’s disease and ulcerative colitis—have many available treatments on the market today, but it remains a major unmet medical need: current treatments are costly, require inconvenient injection delivery, and come with severe side effects. There are no approved therapies at all for mild-to-moderate Crohn’s. A safe, affordable, orally delivered drug to root out IBD at its source is a straightforward application of Lumen's technology, and would constitute a major advance for the field.

Kidney stone disease

Oral biologic cocktail

Product Candidate

Metabolic Disease

(Cardiometabolic Disease)

Initiated Spring 2021

Mode of action: Metabolic signaling

Preclinical

Innovation pipeline

Gastroenteritis

Antibody coctail

Influenza & Covid-19

Intranasal biologic

Product Candidate

Covid-19

(SARS-CoV-2)

Initiated Summer 2020

Mode of action: Neutralizing antibody cocktail

IND Prep

Covid-19 is widely known as a respiratory disease, but its GI symptoms are well documented. The now-famous ACE2 receptor is abundantly expressed on the cells lining the GI tract, and over half of Covid-19 sufferers show symptoms of GI distress, and up to a quarter show only GI symptoms. GI infection by the virus can have serious long-term effects, and high enteric viral loads are thought to contribute to fatalities from acute respiratory distress syndrome (ARDS) and wet-lung disease. Lumen’s Covid-19 product is designed to block GI infection and rapidly flush the virus from the GI tract, thereby reducing disease symptoms and potentially reducing transmission rates.

Malaria

Intranasal vaccine